NCT02258321

Phase 1 Study of Relative Bioavailability of PPI-668 New Tablet Versus Capsule Formulations

A Phase 1, Open-Label, Crossover Study to Evaluate the Relative Bioavailability of a New Tablet Formulation Versus the Current Capsule Formulation of PPI-668 in Healthy Adult Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Presidio Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study will compare the blood levels of PPI-668 resulting from two different formulations - the current capsule and a new tablet, T003.

Conditions

• Pharmacokinetic Assessments in Healthy Volunteers

Interventions

Type	Name	Description
DRUG	PPI-668 tablet
DRUG	PPI-668 capsule

Timeline

• Start date: 2014-10-01
• Primary completion: 2014-10-01
• Completion: 2014-12-01
• First posted: 2014-10-07
• Last updated: 2015-01-22

Locations

1 site across 1 country: United States